Asgard Therapeutics is specialized in R&D and in the use of direct cell reprogramming technologies for cancer immunotherapy.
Location: Sweden, Scania, Lund
Employees: 1-10
Phone: +46 914 76 53 35
Total raised: $39.74M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 15.11.2021 | Industrifo... | industrifo... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.03.2024 | Series A | $32.79M | - |
| 09.11.2021 | Seed | $6.95M | Industrifo... |
Mentions in press and media 5
| Date | Title | Description |
| 17.03.2024 | Asgard Therapeutics: Pioneering Cancer Immunotherapy | Asgard Therapeutics, a biotech company leading the way in in vivo direct cell reprogramming for cancer immunotherapy, has secured a hefty €30 million in Series A funding. This funding injection will propel the development of Asgard's flagsh... |
| 14.03.2024 | Asgard Therapeutics Raises €30M in Series A Financing | Asgard Therapeutics, a Lund, Sweden-based biotech company developing in vivo direct cell reprogramming for cancer immunotherapy, raised €30M in Series A funding. The round was led by RV Invest and Johnson & Johnson Innovation – JJDC, In... |
| 09.11.2021 | Asgard Therapeutics raises €6M in seed financing, co-led by Industrifonden | We are very happy to announce that we have co-led a EUR 6 million seed financing round in Asgard Therapeutics AB (“Asgard”), together with Novo Holdings and Boehringer Ingelheim Venture Fund. Asgard is a private biotech company pioneering ... |
| - | Asgard Therapeutics: In Vivo Cell Reprogramming Company Secures €30 Million | Asgard Therapeutics, a biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, announced it raised €30 million in Series A funding. This funding round will support the development of Asgard´s lead program AT-1... |
| - | Asgard Therapeutics | “Developing a cancer immunotherapy based on direct cell reprogramming - ASGARD THERAPEUTICS” |